Aeterna Zentaris & Er-Kim Announce Partnership to Commercialize Macrilen in Eight European Countries
Istanbul, Turkey – January 31, 2022 – Er-Kim, a regional specialty pharmaceutical company, announced today the signature of an exclusive...
top of page
Search
Er-Kim Public Relations
- Jun 30, 2021
- 4 min
Er-Kim Announces Distribution Agreement and Acceptance of Application for BRUKINSA® in Turkey
Er-Kim Announces Exclusive Distribution Agreement and Acceptance of Priority New Drug Application for BTK Inhibitor BRUKINSA®...
Er-Kim Public Relations
- Jun 29, 2021
- 6 min
Distribution agreement with Er-Kim for Bulgaria and Romania
Extends relationship with Er-Kim following Turkey agreement for Alkindi® and Efmody® Diurnal Group plc (AIM: DNL), the specialty...
Er-Kim Public Relations
- Jan 24, 2021
- 2 min
Erkim Signs Agreement with Diurnal for the Distribution of ALKINDI® and CHRONOCORT® in Turkey
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases,...
Er-Kim Public Relations
- Oct 14, 2020
- 3 min
AnGes and Er-Kim enter into an agreement for the commercialization of Collategene® in Turkey
October 8, 2020, AnGes, Inc., a Japanese biopharmaceutical company focused on gene-based medicines and Er-Kim, a leading Turkish...
bottom of page